MedicineOncologyPharmacologyApoptosisMolecular OncologyPrecision OncologyBreast Cancer PharmacotherapyCancer Cell SignalingCell Cycle PharmacologySignal Transduction In CancerTargeted Cancer TherapyApoptosis TargetingBreast Cancer Resistance MechanismsCancer Cell ApoptosisCancer Cell Proliferation InhibitionHippo SignalingHippo Signaling PathwayHistone Deacetylase TargetsTriple-negative Breast Cancer Therapy
. Our data suggested that anti-HSP90 and anti-HDAC6 are promising strategies to treat TNBC and ERα+ breast cancers respectively, and anti-HDAC6 can be considered during treatment of tamoxifen-resistance breast cancers.
27
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve, Koei Chin, Jane Fridlyand et al. · Cancer Cell · 2006 · 3.2K citations · Full text
Medicine, Cell Biology, Oncology +14
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Adeela Kamal, Lia Thao, John Sensintaffar et al. · Nature · 2003 · 1.4K citations
Medicine, Oncology, Pharmacology +10